Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for determining the risk of prenatal complications

A risky, individual technique for use in biochemical devices and methods, patient-specific data, microbiological assays/tests, etc.

Active Publication Date: 2011-10-12
WALLAC
View PDF7 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Even so, no routine screening has been done to detect preeclampsia early using maternal samples

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for determining the risk of prenatal complications
  • Methods for determining the risk of prenatal complications
  • Methods for determining the risk of prenatal complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1. Clinical study of the role of PlGF, PAPP-A and biophysical markers in the detection of preeclampsia bed study

[0079] This example illustrates the effectiveness of various combinations of biochemical and biophysical markers, including maternal blood pressure, uterine Doppler pulsatility index, PlGF, PAPP- A and PP13.

[0080] Studies were conducted to screen for adverse pregnancy outcomes in women participating in routine assessment for risk of chromosomal abnormalities. Maternal characteristics and medical history were recorded and blood was collected. Serum was stored at -80°C for subsequent biochemical analysis. Written informed consent was obtained from female patients who agreed to participate in this study, which was approved by the King's College Hospital Ethics Committee. Additional information regarding clinical populations and sample collection is described in Example 3.

[0081] For the analyzes described herein, all biochemical and biophy...

Embodiment 2

[0130] Example 2: When multiple biochemical and biophysical markers are used to detect preeclampsia and related placental disorders Clinical research on the role of

[0131] This example illustrates the effectiveness of a combination of multiple biochemical markers for determining the risk of preeclampsia and related disorders in pregnant individuals. Specifically, the biochemical markers MMP3, PlGF, TNFR1 and PP13 (PerkinElmer DELFIA assay format) have been found to be statistically significant for predicting pre-eclampsia and related disorders. One or more markers shown to be predictive for the detection of pre-eclampsia can be used in combination with the marker panels described herein (eg, PlGF and / or PAPP-A and MAP).

[0132] Studies were conducted to screen for adverse pregnancy outcomes in women participating in routine assessment for risk of chromosomal abnormalities. Maternal characteristics and medical history were recorded and blood was collected. Serum was st...

Embodiment 3

[0171] Example 3.: Clinical study of the role of biochemical markers and Doppler biophysical markers in the detection of maternal hypertensive disorders

[0172] This example illustrates the effectiveness of a combination of various biochemical and biophysical markers, including PlGF, PAPP-A, uterine artery PI.

[0173] A study was conducted to screen for adverse pregnancy outcomes in women who participated in routine assessment for risk of chromosomal abnormalities by assessing pregnancy11 +0 -13 +6 The thickness of the fetal cervical translucence membrane (thickness) and the measurement of maternal serum PAPP-A and free β-hCG were carried out. Maternal characteristics and medical history were recorded, and uterine artery PI was measured by transabdominal color Doppler, and serum was stored at -80°C for subsequent biochemical analysis. Written informed consent was obtained from female patients who agreed to participate in this study, which was approved by the King's Colleg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.

Description

[0001] Cross References to Related Applications [0002] Pursuant to 35 U.S.C. Section 119, this application claims priority to the following U.S. provisional applications: 61 / 023,776 filed January 25, 2008, 61 / 025,890 filed February 4, 2008, and June 9, 2008 61 / 060,048, and 61 / 060,732, filed June 11, 2008, the entire contents of which are hereby incorporated by reference. Background of the invention [0003] Every year, at least 126 million women give birth worldwide. More than 20 million of these women suffered from pregnancy-related complications or diseases. For example, hypertensive disorders such as pre-eclampsia affect more than 10% of all pregnancies and lead to maternal mortality. Adequate antenatal care reduces the chance of ignoring such complications and diseases in the future. Screening methods to determine the risk of prenatal complications and / or fetal abnormality have become routine in many countries and are used to aid in the treatment and counseling of pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/16G16H10/60G16H50/30
CPCG01N33/689G01N2333/471G01N2333/515G01N2800/368G16H50/30G01N33/6893A61B5/021G01N2800/50
Inventor 霍华德·库克勒基普罗斯·尼古莱德斯塔加·阿霍拉里昂娜·普恩
Owner WALLAC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com